Abstract
In radiotherapy for cervical cancer, because brachytherapy can provide concentrated dose to the primary tumor, midline block (central shielding) has been applied at least partially in external beam therapy to lower the dose to rectum and bladder and avoid severe complications. Although this practice has been decreased over the years globally, the central shielding technique continues to be used as standard in Japan. The use of central shielding in Japan has resulted in relatively low incidence of late complications in the rectum and bladder without compromising the disease control. Recent study of composite dose distributions of the treatment regimen using central shielding revealed its characteristics which explains the benefit of this technique. This chapter will cover the history, philosophy, analysis of composite dose distributions, issues of dose reporting, and the future prospect of this technique.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tod M, Meredith W. A dosage system for use in the treatment of cancer of the uterine cervix. Brit J Radiol. 1938;11:809–23.
Fletcher GH. Roentgen treatment of cancer of the cervix. Radiology. 1950;54(6):832–42.
Perez C, Kavanagh B. Uterine cervix. In: Halperin E, Perez C, Brady L, editors. Principles and practice of radiation oncology. 5th ed. PA: Lippincott Williams & Wilkins; 2008. p. 1532–609.
Wolfson AH, Abdel-Wahab M, Markoe AM, Raub WJ Jr, Diaz D, Desmond JJ, et al. A quantitative assessment of standard vs. customized midline shield construction for invasive cervical carcinoma. Int J Radiat Oncol Biol Phys. 1997;37(1):237–42.
Viswanathan AN, Beriwal S, De Los Santos JF, Demanes DJ, Gaffney D, Hansen J, et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose-rate brachytherapy. Brachytherapy. 2012;11(1):47–52.
Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137–43.
Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339–48.
Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144–53.
Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20(4):966–72.
Potter R, Knocke TH, Fellner C, Baldass M, Reinthaller A, Kucera H. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993–1997) compared to the preceding period in the context of ICRU 38 recommendations. Cancer Radiother. 2000;4(2):159–72.
Potter R, Georg P, Dimopoulos JC, Grimm M, Berger D, Nesvacil N, et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol. 2011;100(1):116–23.
Mazeron R, Fokdal LU, Kirchheiner K, Georg P, Jastaniyah N, Segedin B, et al. Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: results from the prospective multicenter EMBRACE study. Radiother Oncol. 2016;120(3):412–9.
Report 89. Journal of the ICRU. 2013;13(1–2):Np.
Tazaki E. Historical development of radiotherapy for the uterine cervical cancer in Japan. J Jpn Soc Ther Radiol Oncol. 1999;11:157–73.
Arai T, Akanuma A, Ikeda M, Inoue T, Kasamatsu T, Kubo H, et al. Standardized radiation treatment method for carcinoma of the uterine cervix. Jpn J Cancer Clin. 1984;30(5):496–500.
Shigematsu Y, Nishiyama K, Masaki N, Inoue T, Miyata Y, Ikeda H, et al. Treatment of carcinoma of the uterine cervix by remotely controlled afterloading intracavitary radiotherapy with high-dose rate: a comparative study with a low-dose rate system. Int J Radiat Oncol Biol Phys. 1983;9(3):351–6.
Okawa T, Kita M, Goto M, Tazaki E. Radiation therapy alone in the treatment of carcinoma of the uterine cervix: review of experience at Tokyo Women’s Medical College (1969–1983). Int J Radiat Oncol Biol Phys. 1987;13(12):1845–9.
Teshima T, Chatani M, Hata K, Inoue T. High-dose rate intracavitary therapy for carcinoma of the uterine cervix: I. General figures of survival and complication. Int J Radiat Oncol Biol Phys. 1987;13(7):1035–41.
Akine Y, Arimoto H, Ogino T, Kajiura Y, Tsukiyama I, Egawa S, et al. Carcinoma of the uterine cervix treated by irradiation alone. Results of treatment at the National Cancer Center, Tokyo. Acta Oncol. 1990;29(6):747–53.
Arai T, Nakano T, Morita S, Sakashita K, Nakamura YK, Fukuhisa K. High-dose-rate remote afterloading intracavitary radiation therapy for cancer of the uterine cervix. A 20-year experience. Cancer. 1992;69(1):175–80.
Ito H, Kutuki S, Nishiguchi I, Shigematsu N, Kuribayashi T, Uematsu M, et al. Radiotherapy for cervical cancer with high-dose rate brachytherapy correlation between tumor size, dose and failure. Radiother Oncol. 1994;31(3):240–7.
Mitsuhashi N, Takahashi M, Nozaki M, Yamakawa M, Takahashi T, Sakurai H, et al. Evaluation of external beam therapy and three brachytherapy fractions for carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1994;29(5):975–82.
Ogino I, Kitamura T, Okamoto N, Yamasita K, Aikawa Y, Okajima H, et al. Late rectal complication following high dose rate intracavitary brachytherapy in cancer of the cervix. Int J Radiat Oncol Biol Phys. 1995;31(4):725–34.
Uno T, Itami J, Aruga M, Kotaka K, Fujimoto H, Sato T, et al. High dose rate brachytherapy for carcinoma of the cervix: risk factors for late rectal complications. Int J Radiat Oncol Biol Phys. 1998;40(3):615–21.
Hareyama M, Sakata K, Oouchi A, Nagakura H, Shido M, Someya M, et al. High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: a randomized trial. Cancer. 2002;94(1):117–24.
Toita T, Kakinohana Y, Ogawa K, Adachi G, Moromizato H, Nagai Y, et al. Combination external beam radiotherapy and high-dose-rate intracavitary brachytherapy for uterine cervical cancer: analysis of dose and fractionation schedule. Int J Radiat Oncol Biol Phys. 2003;56(5):1344–53.
Nakano T, Kato S, Ohno T, Tsujii H, Sato S, Fukuhisa K, et al. Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer. 2005;103(1):92–101.
Toita T, Kato S, Niibe Y, Ohno T, Kazumoto T, Kodaira T, et al. Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2). Int J Radiat Oncol Biol Phys. 2012;82(1):e49–56.
Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, et al. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule. Gynecol Oncol. 2012;126(2):211–6.
Ariga T, Toita T, Kato S, Kazumoto T, Kubozono M, Tokumaru S, et al. Treatment outcomes of patients with FIGO Stage I/II uterine cervical cancer treated with definitive radiotherapy: a multi-institutional retrospective research study. J Radiat Res. 2015;56(5):841–8.
Ohno T, Noda SE, Okonogi N, Murata K, Shibuya K, Kiyohara H, et al. In-room computed tomography-based brachytherapy for uterine cervical cancer: results of a 5-year retrospective study. J Radiat Res. 2017;58(4):543–51.
Macdonald DM, Lin LL, Biehl K, Mutic S, Nantz R, Grigsby PW. Combined intensity-modulated radiation therapy and brachytherapy in the treatment of cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71(2):618–24.
Fenkell L, Assenholt M, Nielsen SK, Haie-Meder C, Potter R, Lindegaard J, et al. Parametrial boost using midline shielding results in an unpredictable dose to tumor and organs at risk in combined external beam radiotherapy and brachytherapy for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2011;79(5):1572–9.
Perez CA, Breaux S, Madoc-Jones H, Camel HM, Purdy J, Sharma S, et al. Correlation between radiation dose and tumor recurrence and complications in carcinoma of the uterine cervix: stages I and IIA. Int J Radiat Oncol Biol Phys. 1979;5(3):373–82.
Potter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78(1):67–77.
Tamaki T, Ohno T, Noda SE, Kato S, Nakano T. Filling the gap in central shielding: three-dimensional analysis of the EQD2 dose in radiotherapy for cervical cancer with the central shielding technique. J Radiat Res. 2015;56(5):804–10.
Tamaki T, Noda SE, Ohno T, Kumazaki Y, Kato S, Nakano T. Dose-volume histogram analysis of composite EQD2 dose distributions using the central shielding technique in cervical cancer radiotherapy. Brachytherapy. 2016;15(5):598–606.
Kato S, Ohno T, Thephamongkhol K, Chansilpa Y, Yuxing Y, Devi CR, et al. Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in East and Southeast Asia. Int J Radiat Oncol Biol Phys. 2010;77(3):751–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Tamaki, T. (2019). Midline Block (Central Shielding). In: Yoshioka, Y., Itami, J., Oguchi, M., Nakano, T. (eds) Brachytherapy. Springer, Singapore. https://doi.org/10.1007/978-981-13-0490-3_6
Download citation
DOI: https://doi.org/10.1007/978-981-13-0490-3_6
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-0489-7
Online ISBN: 978-981-13-0490-3
eBook Packages: MedicineMedicine (R0)